



Final Appraisal Recommendation

Ferric carboxymaltose (Ferinject[®]▼)

Submission by:
Vifor Pharma UK Limited

Advice No: 1011 – July 2011

Recommendation of AWMSG

Ferric carboxymaltose (Ferinject[®]▼) is recommended as an option for use within NHS Wales for the treatment of patients with iron deficiency when oral iron preparations are ineffective or cannot be used.

Ferric carboxymaltose (Ferinject[®]▼) should be restricted for use in non-haemodialysis patients only.

AWMSG is of the opinion that Ferric carboxymaltose (Ferinject[®]▼) is not suitable for shared care within NHS Wales for the above indication.

Additional notes:

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report, the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion, lay/patient/carer perspective and discussions at AWMSG.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: